JP2019519553A - ペグ化ブタインターフェロンおよびその使用方法 - Google Patents
ペグ化ブタインターフェロンおよびその使用方法 Download PDFInfo
- Publication number
- JP2019519553A JP2019519553A JP2018566519A JP2018566519A JP2019519553A JP 2019519553 A JP2019519553 A JP 2019519553A JP 2018566519 A JP2018566519 A JP 2018566519A JP 2018566519 A JP2018566519 A JP 2018566519A JP 2019519553 A JP2019519553 A JP 2019519553A
- Authority
- JP
- Japan
- Prior art keywords
- pinf
- variant
- seq
- mutant
- pegylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- 102000014150 Interferons Human genes 0.000 title description 4
- 108010050904 Interferons Proteins 0.000 title description 4
- 229940079322 interferon Drugs 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 150000001413 amino acids Chemical class 0.000 claims abstract description 30
- 238000009472 formulation Methods 0.000 claims abstract description 24
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract description 21
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract description 21
- 230000009385 viral infection Effects 0.000 claims abstract description 20
- 208000036142 Viral infection Diseases 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 241000282898 Sus scrofa Species 0.000 claims description 35
- 239000004234 Yellow 2G Substances 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 22
- 229930182817 methionine Natural products 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 241000282887 Suidae Species 0.000 claims description 13
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000004229 Alkannin Substances 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
- 241000202347 Porcine circovirus Species 0.000 claims description 4
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 210000004392 genitalia Anatomy 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 208000022555 Genital disease Diseases 0.000 claims description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000001268 conjugating effect Effects 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 238000003780 insertion Methods 0.000 abstract description 8
- 230000037431 insertion Effects 0.000 abstract description 8
- 235000001014 amino acid Nutrition 0.000 description 31
- 229940024606 amino acid Drugs 0.000 description 28
- 229920001223 polyethylene glycol Polymers 0.000 description 27
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 23
- 229960002429 proline Drugs 0.000 description 23
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 20
- 229960004452 methionine Drugs 0.000 description 19
- 229960001153 serine Drugs 0.000 description 19
- 239000002202 Polyethylene glycol Substances 0.000 description 18
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 241000282894 Sus scrofa domesticus Species 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- 241001361508 Porcine deltacoronavirus Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 2
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 102000005421 acetyltransferase Human genes 0.000 description 2
- 108020002494 acetyltransferase Proteins 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229940072293 axid Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000001726 Classical Swine Fever Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000005227 N-Terminal Acetyltransferases Human genes 0.000 description 1
- 108010056296 N-Terminal Acetyltransferases Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101100395023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-7 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- AFWBWPCXSWUCLB-WDSKDSINSA-N Pro-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 AFWBWPCXSWUCLB-WDSKDSINSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000007798 antifreeze agent Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000013019 capto adhere Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000002741 methionine derivatives Chemical class 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
(a)pINF-αを精製する工程;
(b)精製pINF-α変異体を、pH8にて、50mM Tris、6Mグアニジンに可溶化する工程;
(c)可溶化pINF-αA変異体を、pH8にて、20mM Tris、1Mアルギニン、10mMメチオニン(met)、1mM EDTA(エチレンジアミン四酢酸)中、室温にて16-24時間インキュベートして、タンパク質のリフォールディングを可能にする工程;
(d)残留アセチル化変異体を、強陰イオン交換樹脂上のクロマトグラフィー分割によって除去する工程;
(e)pINF-α変異体を、1:1〜1:8または1:1〜1:2のPEG:タンパク質比にてPEGでコンジュゲートさせる工程;および
(f)ペグ化pINF-α変異体を精製する工程;
を含む方法によって製造することができる。
11のpAF変異体を作製し、野生型pINF-α(wt)と比較する。これらのうち、3つのpINF-α変異体は、pINF-α内のさまざまな位置で置換された合成アミノ酸についての乏しいタンパク質発現/産生の問題が原因で、継続的な試験から除外される。
18匹のスプラーグドーリーラット(n=3グループ)は、6つの試験サンプル(20mM酢酸ナトリウム、pH5.0、100mM NaCl、および5%グリセロール中に再懸濁されたもの)のそれぞれ0.2mg/kgを、首の首筋に、カテーテルの遠位で皮下投与される:(1)pIFNα-E103-PEG30K(ペグ化された配列番号:9)、(2)pIFNα-L112-PEG30K(ペグ化された配列番号:15)、(3)pIFNα-E107-PEG30K(ペグ化された配列番号:12)、(4)pIFNα-Y136-PEG30K(ペグ化された配列番号:18)、および(5)pIFNα-a-Q102-PEG30K(ペグ化された配列番号:6)。
第3表:ペグ化されたIFN-α変異体のバイオアベイラビリティ
pIFN-αA-E107(配列番号:12)の質量分析(MS)に基づいて、アセチル化形態、58Da形態および酸化汚染物質が存在する。変異体は、大腸菌産生株内で生合成中にアセチル化される。したがって、pIFN-αA-E107生成のための1つの選択肢は、適切な生成時にアセチルトランスフェラーゼを添加するか、またはノックアウトリボソーム-タンパク質-アラニンアセチルトランスフェラーゼ(RimJ)(N末端アセチルトランスフェラーゼ)を使用することである。さらに、小規模および大規模クロマトグラフィーを精製のために使用することができる。別法として、および本明細書に示されるように、アセチル化が変異体上で完全には起こらないように、N末端配列をさらに修飾することができる。
pIFNα-E107pAFのN末端へのプロリン付加の成功を前提として、pIFNα-E107pAFへのセリン(Ser、S)付加、Pro-Ser(PS)付加、His(H)、およびSer-Gly(SG)付加を含む他のN末端変異体もまた評価した。これらのN末端変異体は、ペグ化されない。次いで、これらのN末端変異体(全てE107-pAF変異体である)の活性を、上述のPestka Biomedical LaboratoriesによるiLite(登録商標)huIFNαキットを用いるインビトロバイオアッセイにおいて評価し、結果を表5に示す。
pINFα-PS-E107変異体(配列番号:14)を、製造業者の指示にしたがってCaptoクロマトグラフィーを使用した後にカプト(Capto)クロマトグラフィープールから取り出し、精製形態に0.2Mグリシンを添加する。混合物のペプチドを酢酸で4.0に調整する。次いで、製造者の指示にしたがって、アミコン・ウルトラ(Amicon Ultra)遠心フィルターを用いてpINF-α変異体を8.2mg/mLに濃縮する。濃縮したら、30K直鎖状PEG(PEGは、たとえば、NOF America CorporationまたはEMD Merckから購入可能である)を、PEG:pINFα変異体のモル比8:1で付加する。次いで、PEG/pINF-α変異体混合物を28℃にて約18時間インキュベートする。この方法は、18時間のインキュベーション後に95%を超えるpINF-α変異体がPEGとコンジュゲートすることをもたらす。
A:30mM酢酸ナトリウム、pH5.0
B:30mM酢酸ナトリウム、5%エチレングリコール、pH5.0
20カラム体積にわたって0〜100% B。
E107で置換されたpAFを有し、アミノ末端でプロリン-セリンを有する変異体(配列番号:14)に対するペグ化の影響を評価するために、それらのペグ化(30KDa直鎖状PEG)および非ペグ化形態の両方におけるいくつかの変異体について、活性アッセイを実施する。結果を下記第6表に提供する。タンパク質濃度、SEC、RP、およびEC50値は、上記のように決定される。pIFNα-P-E107-pAFを、アミノ末端伸長なしのタンパク質についての結果を反映するための比較サンプルとして使用する。
サンプルを1.5mLチューブ中で0℃にて凍結し、室温の水浴中で解凍することにより、5サイクルにわたって凍結および解凍した。下記の第7表において証明されるように、5サイクルの凍結融解にわたって、高分子量(HMW)タンパク質プロファイルについて有意な影響は観察されなかった。
第7表
Claims (30)
- 合成アミノ酸が、パラアセチルフェニルアラニン(pAF)である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:7である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:10である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:13である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:16である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:19である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:8である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:11である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:14である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:17である、請求項1に記載のpINF-α変異体。
- 変異体が、配列番号:20である、請求項1に記載のpINF-α変異体。
- 合成アミノ酸が、ペグ化される、請求項1〜12のいずれかに記載のpINF-α変異体。
- ペグ化pINF-α変異体が、約5kDa〜40kDaのPEGでペグ化される、請求項13に記載のpINF-α変異体。
- PEGが、30kDaのPEGである、請求項14に記載のpINF-α変異体。
- 20mMの酢酸ナトリウム、100mMの塩化ナトリウム、5%のグリセロール、pH5.0で約2.0〜約6.0g/Lの力価のpINF-α変異体を含む、請求項1〜16のいずれかに記載のpINF-α変異体を含む製剤。
- 請求項1に記載のpINF-α変異体を製造する方法であって、
以下の工程:
(a)pINF-αを精製する工程;
(b)精製pINF-α変異体を、pH8にて、50mM Tris、6Mグアニジンに可溶化する工程;
(c)可溶化pINF-αA変異体を、pH8にて、20mM Tris、1Mアルギニン、10mMメチオニン(met)、1mM EDTA中、室温にて16-24時間インキュベートする工程;
(d)残留アセチル化変異体を除去する工程;
(e)pINF-α変異体を、1:1〜1:2のPEG:タンパク質比にてPEGでコンジュゲートさせる工程;および
(f)ペグ化pINF-α変異体を精製する工程;
を含む方法。 - それを必要とするブタに、請求項1〜16のいずれかに記載のpINF-α変異体を皮下投与することを含む、ブタのウイルス感染を予防または治療する方法。
- pINF-α変異体が、動物の体重kg当たり25μg/kg〜150μg/kgの範囲で投与される、請求項19に記載の方法。
- 動物の体重kg当たり25μg/kg〜150μg/kgのpINF-α変異体の第二の投与を含む、害請求項20に記載の方法であって、該pINF-α変異体。
- 第二の投与が、第一の投与の7〜14日後である、請求項21に記載の方法。
- ウイルス感染が、ブタ生殖器および呼吸器疾患ウイルス、口蹄疫ウイルス、ブタインフルエンザウイルス、ブタサーコウイルス、ブタ流行性下痢ウイルスおよび伝染性胃腸炎ウイルスからなる群から選択される、請求項19に記載の方法。
- ブタが、新生ブタであるか、または妊娠中のブタである、請求項19〜23のいずれかに記載の方法。
- 請求項17に記載のpIFN-α変異体を含有する複数回投与用バイアル。
- ウイルス感染を治療するためのブタにおける療法における、請求項1〜16のいずれかに記載のpINF-α変異体の使用。
- 療法のための請求項1〜16のいずれかに記載のpINF-α変異体の使用。
- ブタにおけるウイルス感染を治療するための、請求項17に記載の製剤または請求項1〜16のいずれかに記載のpINF-α変異体の使用。
- ブタにおけるウイルス感染を治療するための医薬の製造における使用のための、請求項17に記載の製剤または請求項1〜16のいずれかに記載のpINF-α変異体の使用。
- ブタが、新生ブタまたは妊娠中のブタである、請求項28または29のいずれかに記載のpIFN-α変異体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022098147A JP7441892B2 (ja) | 2016-06-20 | 2022-06-17 | ペグ化ブタインターフェロンおよびその使用方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352163P | 2016-06-20 | 2016-06-20 | |
US62/352,163 | 2016-06-20 | ||
PCT/US2017/037964 WO2017222940A1 (en) | 2016-06-20 | 2017-06-16 | Pegylated porcine interferon and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022098147A Division JP7441892B2 (ja) | 2016-06-20 | 2022-06-17 | ペグ化ブタインターフェロンおよびその使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019519553A true JP2019519553A (ja) | 2019-07-11 |
JP2019519553A5 JP2019519553A5 (ja) | 2020-01-30 |
JP7093311B2 JP7093311B2 (ja) | 2022-06-29 |
Family
ID=59258379
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018566519A Active JP7093311B2 (ja) | 2016-06-20 | 2017-06-16 | ペグ化ブタインターフェロンおよびその使用方法 |
JP2022098147A Active JP7441892B2 (ja) | 2016-06-20 | 2022-06-17 | ペグ化ブタインターフェロンおよびその使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022098147A Active JP7441892B2 (ja) | 2016-06-20 | 2022-06-17 | ペグ化ブタインターフェロンおよびその使用方法 |
Country Status (18)
Country | Link |
---|---|
US (2) | US10960080B2 (ja) |
EP (1) | EP3471755B1 (ja) |
JP (2) | JP7093311B2 (ja) |
KR (2) | KR102409470B1 (ja) |
CN (2) | CN117024562A (ja) |
AU (2) | AU2017280958A1 (ja) |
BR (1) | BR112018076437A2 (ja) |
CA (1) | CA3028683A1 (ja) |
CL (1) | CL2018003697A1 (ja) |
DK (1) | DK3471755T3 (ja) |
EA (1) | EA036509B1 (ja) |
ES (1) | ES2793773T3 (ja) |
MX (1) | MX2018016295A (ja) |
NZ (1) | NZ749962A (ja) |
PL (1) | PL3471755T3 (ja) |
PT (1) | PT3471755T (ja) |
WO (1) | WO2017222940A1 (ja) |
ZA (1) | ZA201808352B (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
HRP20221216T1 (hr) | 2016-12-22 | 2022-12-23 | Incyte Corporation | Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1 |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
CN110343164A (zh) * | 2019-08-22 | 2019-10-18 | 安阳工学院 | 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用 |
AU2020357514A1 (en) | 2019-09-30 | 2022-04-07 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
CN113845599B (zh) * | 2021-11-01 | 2023-09-19 | 长春萤火虫生物科技有限公司 | 一种重组猪干扰素融合蛋白及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09506087A (ja) * | 1993-11-10 | 1997-06-17 | エンゾン,インコーポレーテッド | 改良されたインターフェロン−ポリマー複合体 |
JP2008541769A (ja) * | 2005-06-03 | 2008-11-27 | アンブレツクス・インコーポレイテツド | 改善されたヒトインターフェロン分子及びそれらの使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858409B1 (en) * | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
JP2006213597A (ja) * | 2000-07-19 | 2006-08-17 | Pepgen Corp | インターフェロン−タウを用いるc型肝炎ウイルスの処置のための組成物およびモニタリングの方法 |
US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
AU2005211385B2 (en) | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
US7695710B2 (en) * | 2005-06-20 | 2010-04-13 | Pepgen Corporation | Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs |
WO2009046080A1 (en) | 2007-10-01 | 2009-04-09 | Pharmaessentia Corp. | N-terminal modified interferon-alpha |
JP5680534B2 (ja) | 2008-07-23 | 2015-03-04 | イーライ リリー アンド カンパニー | 修飾されているウシg−csfポリペプチドおよびそれらの使用 |
CN104262480B (zh) * | 2014-09-28 | 2018-03-27 | 重庆理工大学 | 重组猪长效‑α干扰素的构建和修饰方法及其冻干注射剂的制备方法 |
-
2017
- 2017-06-16 WO PCT/US2017/037964 patent/WO2017222940A1/en unknown
- 2017-06-16 EA EA201892671A patent/EA036509B1/ru unknown
- 2017-06-16 CN CN202310995289.4A patent/CN117024562A/zh active Pending
- 2017-06-16 DK DK17734584.0T patent/DK3471755T3/da active
- 2017-06-16 KR KR1020187036853A patent/KR102409470B1/ko active IP Right Grant
- 2017-06-16 JP JP2018566519A patent/JP7093311B2/ja active Active
- 2017-06-16 BR BR112018076437A patent/BR112018076437A2/pt unknown
- 2017-06-16 MX MX2018016295A patent/MX2018016295A/es unknown
- 2017-06-16 US US16/311,540 patent/US10960080B2/en active Active
- 2017-06-16 ES ES17734584T patent/ES2793773T3/es active Active
- 2017-06-16 NZ NZ749962A patent/NZ749962A/en unknown
- 2017-06-16 CA CA3028683A patent/CA3028683A1/en active Pending
- 2017-06-16 EP EP17734584.0A patent/EP3471755B1/en active Active
- 2017-06-16 KR KR1020227019809A patent/KR102518451B1/ko active IP Right Grant
- 2017-06-16 PT PT177345840T patent/PT3471755T/pt unknown
- 2017-06-16 CN CN201780051072.0A patent/CN109641034B/zh active Active
- 2017-06-16 AU AU2017280958A patent/AU2017280958A1/en not_active Abandoned
- 2017-06-16 PL PL17734584T patent/PL3471755T3/pl unknown
-
2018
- 2018-12-11 ZA ZA2018/08352A patent/ZA201808352B/en unknown
- 2018-12-19 CL CL2018003697A patent/CL2018003697A1/es unknown
-
2021
- 2021-02-26 US US17/186,642 patent/US20210177980A1/en active Pending
- 2021-09-06 AU AU2021229132A patent/AU2021229132B2/en active Active
-
2022
- 2022-06-17 JP JP2022098147A patent/JP7441892B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09506087A (ja) * | 1993-11-10 | 1997-06-17 | エンゾン,インコーポレーテッド | 改良されたインターフェロン−ポリマー複合体 |
JP2008541769A (ja) * | 2005-06-03 | 2008-11-27 | アンブレツクス・インコーポレイテツド | 改善されたヒトインターフェロン分子及びそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
KR20190039889A (ko) | 2019-04-16 |
MX2018016295A (es) | 2019-09-16 |
BR112018076437A2 (pt) | 2019-10-01 |
KR102518451B1 (ko) | 2023-04-04 |
EP3471755B1 (en) | 2020-04-22 |
AU2017280958A1 (en) | 2018-12-20 |
US10960080B2 (en) | 2021-03-30 |
KR102409470B1 (ko) | 2022-06-16 |
EA036509B1 (ru) | 2020-11-18 |
JP7093311B2 (ja) | 2022-06-29 |
NZ749962A (en) | 2020-06-26 |
EA201892671A1 (ru) | 2019-05-31 |
US20190192673A1 (en) | 2019-06-27 |
CN109641034A (zh) | 2019-04-16 |
CN109641034B (zh) | 2023-08-15 |
AU2021229132B2 (en) | 2023-04-06 |
JP7441892B2 (ja) | 2024-03-01 |
CL2018003697A1 (es) | 2019-05-10 |
ES2793773T3 (es) | 2020-11-16 |
PL3471755T3 (pl) | 2020-10-19 |
PT3471755T (pt) | 2020-05-22 |
WO2017222940A1 (en) | 2017-12-28 |
DK3471755T3 (da) | 2020-05-18 |
KR20220086700A (ko) | 2022-06-23 |
JP2022137063A (ja) | 2022-09-21 |
ZA201808352B (en) | 2020-08-26 |
US20210177980A1 (en) | 2021-06-17 |
EP3471755A1 (en) | 2019-04-24 |
CA3028683A1 (en) | 2017-12-28 |
CN117024562A (zh) | 2023-11-10 |
AU2021229132A1 (en) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7441892B2 (ja) | ペグ化ブタインターフェロンおよびその使用方法 | |
US8168751B2 (en) | Interferon alpha mutant and its polyethylene glycol derivative | |
KR20090089316A (ko) | Peg 변형된 엑센딘 또는 엑센딘 유사체 및 조성물 및 이의 용도 | |
US11530249B2 (en) | Long-acting conjugates of GLP-2 derivatives | |
KR20150008137A (ko) | 지속성 옥신토모둘린 변이체 및 이의 생산 방법 | |
EA033788B1 (ru) | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина | |
US20120128629A1 (en) | Method of labelling interferons with peg | |
US10406235B2 (en) | Use of multi-arm polyethylene glycol modifier and application of multi-arm polyethylene glycol modifier in L-asparaginasum modification | |
JPH10503523A (ja) | Asp▲上b1▼インシュリンアナログ | |
CA2710841A1 (en) | Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof | |
WO2005105151A1 (fr) | Derives pegyles de thymosine 1 | |
KR20220097921A (ko) | 인터루킨-22의 치료 유도체 | |
RU2488598C2 (ru) | Гормон роста, модифицированный двухцепочечным полиэтиленгликолем, способ его получения и применение | |
EP3925617A1 (en) | Recombinant protein for eliminating boar taint and vaccine composition comprising same | |
US20240052330A1 (en) | Blockade of sars-cov-2 infection using hydrocarbon stapled peptides | |
TW201703793A (zh) | 聚乙二醇化介白素-11之組合物及方法 | |
CN101385858B (zh) | 纯化的peg化人生长激素缀合物及其药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191211 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210416 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210707 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220404 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220419 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220518 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220617 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7093311 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |